Compare HI & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HI | IMNM |
|---|---|---|
| Founded | 2007 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.2B |
| IPO Year | N/A | 2020 |
| Metric | HI | IMNM |
|---|---|---|
| Price | $31.87 | $25.83 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $32.00 | $31.22 |
| AVG Volume (30 Days) | 655.8K | ★ 2.2M |
| Earning Date | 02-04-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.86% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $2,673,800,000.00 | $9,679,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.62 | $11.53 |
| P/E Ratio | $52.20 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $18.36 | $5.15 |
| 52 Week High | $35.59 | $25.30 |
| Indicator | HI | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 62.79 | 69.98 |
| Support Level | $31.81 | $21.39 |
| Resistance Level | $31.86 | $22.01 |
| Average True Range (ATR) | 0.06 | 1.46 |
| MACD | -0.01 | 0.39 |
| Stochastic Oscillator | 84.37 | 96.09 |
Hillenbrand Inc is a industrial company that provides engineered processing equipment and solutions to customers around the world. The company operates through two segments. The Advanced Process Solutions segment designs, develops, manufactures, and services engineered industrial equipment and also provider of engineered process and material handling equipment, systems, and aftermarket parts and services for a variety of industries, including durable plastics, food, and recycling. Molding Technology Solutions has a comprehensive product portfolio that includes injection molding and extrusion equipment, It earns it revenue from Advanced Process Solutions, and Geographically from America, following by Asia and EMEA.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.